This inventor holds 3 USPTO granted patents and 6 published patent applications. Top assignee: Allergan, Inc.. Active years: 2003-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003-2015
Title: **Eldon Q Farnes: Innovator in Ocular Pain Treatment**
Introduction
Eldon Q Farnes is a notable inventor based in Laguna Beach, California, who has made significant contributions to the field of ophthalmic solutions aimed at treating ocular pain. With a total of three patents, Farnes has focused his innovations on enhancing the effectiveness of existing treatments for eye discomfort and promoting better visual outcomes.
Latest Patents
Farnes' latest patents include groundbreaking inventions related to ketorolac tromethamine compositions. The first patent details a novel aqueous ophthalmic solution that combines ketorolac and carboxymethyl cellulose. This unique formulation is designed to provide increased visual acuity. Notably, the concentration of carboxymethyl cellulose is optimized to enhance the absorption of ketorolac in the eye, achieving an absorption rate that is at least 130% greater than that of comparative solutions.
His second patent also involves ketorolac tromethamine compositions but focuses exclusively on the treatment of ocular pain. Similar to the first, this aqueous solution incorporates carboxymethyl cellulose to boost the absorption of ketorolac, thus improving treatment outcomes for patients experiencing eye discomfort.
Career Highlights
Currently, Eldon Q Farnes is affiliated with Allergan, Inc., a leading company in the pharmaceutical sector renowned for its focus on eye care and other health solutions. Farnes has established himself as a key innovator within his field, developing formulations that prioritize patient comfort and enhanced treatment efficacy.
Collaborations
Throughout his career, Farnes has collaborated with other skilled professionals, including Chin-Ming Chang and Mayssa Attar. These partnerships signify the importance of teamwork and diverse expertise in the innovative processes leading to the development of effective ocular treatments.
Conclusion
Eldon Q Farnes exemplifies the spirit of innovation in the medical field, particularly in the realm of ocular pain management. His developments in ketorolac compositions demonstrate a commitment to improving patient care through targeted therapeutic solutions. As he continues to advance his research and patent portfolio, Farnes remains a significant figure in the ongoing evolution of ophthalmic treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile